| Literature DB >> 27302882 |
Nahid Sherbini1, Ayman Iskandrani2, Ayman Kharaba3, Ghalilah Khalid4, Mohammed Abduljawad5, Hamdan Al-Jahdali6.
Abstract
BACKGROUND: Middle East respiratory syndrome coronavirus (MERS-CoV), is an emerging virus respiratory infection. It has a high mortality rate and a wide spectrum of clinical features. This study describes the clinical characteristics and outcome of MERS infected patients.Entities:
Keywords: Characteristics; Coronavirus; Epidemiology; MERS; Saudi Arabia; Survival
Mesh:
Year: 2016 PMID: 27302882 PMCID: PMC7104069 DOI: 10.1016/j.jegh.2016.05.002
Source DB: PubMed Journal: J Epidemiol Glob Health ISSN: 2210-6006
Demographic and clinical characteristics of patients with Middle East respiratory syndrome coronavirus (MERS-CoV) infection according to outcome.
| Clinical characteristics | Died ( | Survived ( | |||
|---|---|---|---|---|---|
| No. | % | No. | % | ||
| Age (y) Mean ± SD | 54.6 ± 13.0 | 40.7 ± 8.5 | 0.002 | ||
| Male | 6 | 60.0 | 14 | 73.7 | 0.675 |
| Female | 4 | 40.0 | 5 | 26.3 | |
| Fever | 9 | 90.0 | 13 | 68.4 | 0.367 |
| Cough | 7 | 70.0 | 13 | 68.4 | 1.0 |
| Shortness of breath | 8 | 80.0 | 12 | 63.2 | 0.431 |
| Vomiting | 7 | 70.0 | 1 | 5.3 | 0.001 |
| Diarrhea | 7 | 70.0 | 1 | 5.3 | 0.001 |
| Diabetes mellitus | 7 | 70.0 | 2 | 10.5 | 0.002 |
| Chronic kidney disease | 8 | 80.0 | 0 | 0.0 | <0.0001 |
| Smoker | 10 | 100.0 | 9 | 47.4 | 0.005 |
| Nonsmoker | 0 | 0.0 | 10 | 52.6 | |
| Min–Max | 4–12 | 1–6 | <0.0001 | ||
| Mean ± SD | 8.1 ± 2.5 | 3.4 ± 1.3 | |||
| Pulse | |||||
| Min–Max | 98–154 | 82–142 | <0.0001 | ||
| Mean ± SD | 132.5 ± 17.0 | 101.0 ± 21.5 | |||
| Min–Max | 37.1–39.0 | 37.0–39.1 | 0.415 | ||
| Mean ± SD | 38.2 ± 0.5 | 38.0 ± 0.6 | |||
| Min–Max | 90–105 | 125–140 | <0.0001 | ||
| Mean ± SD | 98.0 ± 4.8 | 132.6 ± 5.6 | |||
| Min–Max | 55–65 | 70–87 | <0.0001 | ||
| Mean ± SD | 59.0 ± 3.2 | 78.3 ± 6.4 | |||
SD = standard deviation.
Denotes significant p value.
Residence within Al-Madinah area of patients with Middle East respiratory syndrome coronavirus (MERS-CoV) infection – according to outcome.
| Demographic characteristics | Died ( | Survived ( | |||
|---|---|---|---|---|---|
| No. | % | No. | % | ||
| Al-Madinah | 0 | 0.0 | 6 | 31.6 | 0.045 |
| Hanakia | 6 | 60.0 | 5 | 26.3 | |
| Yanbu | 1 | 10.0 | 3 | 15.8 | |
| Wadi Alfara | 0 | 0.0 | 3 | 15.8 | |
| Khaibar | 1 | 10.0 | 2 | 10.5 | |
| Al Mahd | 2 | 20.0 | 0 | 0.0 | |
Denotes significant p value.
Laboratory findings of Middle East respiratory syndrome coronavirus (MERS-CoV) patients according to outcome, April–May 2013/Al-Madinah.
| Laboratory investigations | Studied patients ( | ||
|---|---|---|---|
| Mean ± SD | |||
| Died ( | Survived ( | ||
| WBC | 3.3 ± 0.9 | 9.0 ± 4.0 | <0.0001 |
| Hemoglobin | 11.7 ± 1.5 | 13.2 ± 1.8 | 0.033 |
| Platelets | 253.9 ± 81.5 | 313.8 ± 78.1 | 0.064 |
| pH | 7.2 ± 0.1 | 7.4 ± 0.1 | <0.0001 |
| PCO2 | 64.1 ± 5.2 | 53.5 ± 7.1 | <0.0001 |
| PO2 | 80.3 ± 1.3 | 82.0 ± 1.8 | 0.012 |
| SPO2 | 84.8 ± 3.5 | 91.2 ± 5.0 | 0.001 |
| HCO3 | 22.8 ± 1.3 | 24.5 ± 1.4 | 0.004 |
| ALT | 203.1 ± 125.9 | 43.3 ± 8.8 | |
| AST | 169.6 ± 123.8 | 42.5 ± 6.9 | <0.0001 |
| Bilirubin (total) | 23.0 ± 3.9 | 13.3 ± 2.1 | <0.0001 |
| Bilirubin (direct) | 15.9 ± 2.2 | 12.2 ± 1.3 | <0.0001 |
| Creatinine | 370.8 ± 60.2 | 148.3 ± 29.3 | <0.0001 |
| Urea | 22.5 ± 1.8 | 14.2 ± 2.1 | <0.0001 |
| Sodium | 146.1 ± 7.9 | 139.7 ± 3.9 | 0.033 |
| Potassium | 3.9 ± 0.3 | 3.7 ± 0.3 | 0.065 |
| Magnesium | 0.4 ± 0.2 | 0.3 ± 0.1 | 0.323 |
ABG = arterial blood gases; ALT = alanine transaminase; AST = aspartate aminotransferase.
Denotes significant p value.
Fig. 1Sputum culture results. MRSA = methicillin-resistant Staphylococcus aureus; Staph = Staphylococcus; Strepto = Streptococcus.
Management of Middle East respiratory syndrome coronavirus (MERS-CoV) patients according to outcome, April–May 2013/Al-Madinah.
| Management | Died ( | Survived ( | |||
|---|---|---|---|---|---|
| No. | % | No. | % | ||
| Meropenem | 8 | 80.0 | 12 | 63.2 | 0.431 |
| Linezolid | 4 | 40.0 | 13 | 68.4 | 0.236 |
| Levofloxacin | 7 | 70.0 | 8 | 42.1 | 0.245 |
| Piperacillin | 4 | 40.0 | 11 | 57.9 | 0.450 |
| Ribavirin | 3 | 30.0 | 7 | 36.8 | 1.0 |
| Azithromycin | 6 | 60.0 | 13 | 68.4 | 0.698 |
| Interferon | 6 | 60.0 | 13 | 68.4 | 0.698 |
| Steroids | 10 | 100.0 | 19 | 100.0 | NA |
| Use of mechanical ventilation | 8 | 80.0 | 1 | 5.3 | <0.0001 |
| Duration of ICU stay (d), mean ± SD | 18.5 ± 2.3 | 11.1 ± 1.6 | <0.0001 | ||
ICU = intensive care unit; NA = not applicable; SD = standard deviation.
Denotes significant p value.